Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Jones

Showing results (121-130 of 151) with videos related to

Pageof 16
Sort By:
Blood|March 31, 2010
17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibitionErin Hertlein, Amy J Wagner, Jeffrey Jones, et al.
British Journal of Haematology|May 12, 2010
Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylationKristie A Blum, Zhongfa Liu, David M Lucas, et al.
British Journal of Haematology|June 7, 2018
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trialsJeffrey Jones, Anthony Mato, Steven Coutre, et al.
Blood|June 5, 2010
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signalsSarah E M Herman, Amber L Gordon, Amy J Wagner, et al.
Blood|February 14, 2018
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experienceSusan O'Brien, Richard R Furman, Steven Coutre, et al.
American Journal of Hematology|April 8, 2026
Recurrent Genomic Alterations in BCRi-Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow-UpJennifer A Woyach, Relja Popovic, Emily L Rossi, et al.
Nature Reviews. Urology|April 26, 2019
Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018Yair Lotan, Trinity J Bivalacqua, Tracy Downs, et al.
Blood|December 8, 2009
CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibodyFarrukh T Awan, Rosa Lapalombella, Rossana Trotta, et al.
Molecular Pain|October 27, 2015
MicroRNA circulating in the early aftermath of motor vehicle collision predict persistent pain development and suggest a role for microRNA in sex-specific pain differencesSarah D Linnstaedt, Margaret G Walker, Joel S Parker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2023
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 InsertionsZofia Piotrowska, Daniel Shao-Weng Tan, Egbert F Smit, et al.
Pageof 16

Showing results (121-130 of 151) with videos related to

Sort By:
Pageof 16
Blood|March 31, 2010
17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibitionErin Hertlein, Amy J Wagner, Jeffrey Jones, et al.
British Journal of Haematology|May 12, 2010
Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylationKristie A Blum, Zhongfa Liu, David M Lucas, et al.
British Journal of Haematology|June 7, 2018
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trialsJeffrey Jones, Anthony Mato, Steven Coutre, et al.
Blood|June 5, 2010
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signalsSarah E M Herman, Amber L Gordon, Amy J Wagner, et al.
Blood|February 14, 2018
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experienceSusan O'Brien, Richard R Furman, Steven Coutre, et al.
American Journal of Hematology|April 8, 2026
Recurrent Genomic Alterations in BCRi-Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow-UpJennifer A Woyach, Relja Popovic, Emily L Rossi, et al.
Nature Reviews. Urology|April 26, 2019
Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018Yair Lotan, Trinity J Bivalacqua, Tracy Downs, et al.
Blood|December 8, 2009
CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibodyFarrukh T Awan, Rosa Lapalombella, Rossana Trotta, et al.
Molecular Pain|October 27, 2015
MicroRNA circulating in the early aftermath of motor vehicle collision predict persistent pain development and suggest a role for microRNA in sex-specific pain differencesSarah D Linnstaedt, Margaret G Walker, Joel S Parker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2023
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 InsertionsZofia Piotrowska, Daniel Shao-Weng Tan, Egbert F Smit, et al.
Pageof 16